ISSUE
Search and design about attractive molecules that could have antagonistic properties.
CUSTOMER INFORMATION
Molecular Immunology Center (CIM) . It is a Cuban biotechnological institution with a closed cycle (research-development, production, commercialization), which, based on the cultivation of superior cells, directs its basic research, development and manufacture of products to the treatment of cancer and other autoimmune diseases. It is currently subordinate to the Higher Organization of Business Management (OSDE) BIOCUBAFARMA.
RESULTS OBTAINED WITH THE SUPPORT OF HPC TECHNOLOGY
Study of the interaction of PD1 with PDL1 and different antibodies for the project.
"Rational design of PD1 inhibitors".
The main impact was to recognize a region of PD1 that seems to be important for its signaling and can serve as a localized target for therapies (article in preparation). Furthermore, two strategies were deduced to convert PDL1 into a PD1 antagonist (to be tested experimentally later). The design was also carried out using several applications of mutated PDL1 variants that can bind with higher affinity to PD1 and that could be attractive molecules for use as agonists or antagonists (to be tested experimentally).
Rational design of inflammation inhibitors cancer-associated.
A study was made of the interaction dynamics of IL6 with the alpha receptor and gp130. In addition, the differences induced in this system by hexamerization mediated by the first domain of GP130 were studied. This study was useful for the design of mutated variants of IL6 that may have antagonistic properties (yet to be tested experimentally).
Opinión del Cliente
Get to know closely what we do; check our professionalism and dedication. We show you the experiences in the deployment of our services and products.